Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
Boehringer Ingelheim
Harvard Business School
McKinsey
Express Scripts
Merck

Last Updated: October 16, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,101,161

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,101,161 protect, and when does it expire?

Patent 8,101,161 protects LATISSE and is included in one NDA.

This patent has seventeen patent family members in eight countries.

Summary for Patent: 8,101,161
Title:Method of enhancing hair growth
Abstract: Methods and compositions for stimulating the growth of hair are disclosed wherein said compositions include a cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compound represented by the formula I ##STR00001## wherein the dashed bonds represent a single or double bond which can be in the cis or trans configuration, A, B, Z, X, R.sub.1 and R.sub.2 are as defined in the specification. Such compositions are used in treating the skin or scalp of a human or non-human animal. Bimatoprost is preferred for this treatment.
Inventor(s): Woodward; David F. (Lake Forest, CA), VanDenburgh; Amanda M. (Huntington Beach, CA)
Assignee: Allergan, Inc. (Irvine, CA)
Application Number:11/805,122
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,101,161
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 8,101,161

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Allergan LATISSE bimatoprost SOLUTION/DROPS;TOPICAL 022369-001 Dec 24, 2008 AT RX Yes Yes   Request a Trial   Request a Trial METHOD OF INCREASING HAIR GROWTH   Request a Trial
Allergan LATISSE bimatoprost SOLUTION/DROPS;TOPICAL 022369-001 Dec 24, 2008 AT RX Yes Yes   Request a Trial   Request a Trial METHOD OF STIMULATING HAIR GROWTH   Request a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,101,161

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2003207843   Request a Trial
Australia 2008203212   Request a Trial
Australia 2010227111   Request a Trial
Australia 2012261499   Request a Trial
Australia 2013208002   Request a Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
McKesson
Harvard Business School
Mallinckrodt
Merck
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.